MPN Landmark Survey

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and Ruxolitinib in subjects with myelofibrosis. To obtain further study eligibility details and locate a clinical research site that is participating in this study, please call the Incyte Corporation Call Center [Phone: (855) 463‐3463] or review the additional study information on

Key information from the MPN LANDMARK SURVEY is now available for review and sharing. It includes a summary of the findings and some interviews with the MPN LANDMARK SURVEY steering committee members.

The patient-friendly summary includes separate surveys of patients and physicians about MF, PV, and ET. It highlights the commonalities and differences for these diseases in five key areas:

  • Diagnosis
  • Symptoms
  • Disease impact
  • Treatment and management
  • Patient-physician communications

More importantly, the information illuminates in detail the patient experience with regard to the physical, psychological, emotional, and financial challenges faced by individuals living with MPNs.